Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


Nonclinical immunogenicity risk assessment of therapeutic proteins.

Tourdot S, Hickling TP.

Bioanalysis. 2019 Jun 18. doi: 10.4155/bio-2018-0246. [Epub ahead of print]


Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology.

Vicini P, Standifer N, Hickling TP.

CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):436-439. doi: 10.1002/psp4.12416. Epub 2019 May 24. No abstract available.


Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.

Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E.

J Immunother Cancer. 2019 Apr 15;7(1):105. doi: 10.1186/s40425-019-0586-0. Review.


Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.

Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP.

Clin Exp Immunol. 2018 Jun;192(3):348-365. doi: 10.1111/cei.13112. Epub 2018 Mar 30. Review.


The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.

Yin L, Chen X, Tiwari A, Vicini P, Hickling TP.

J Immunol Res. 2015;2015:401956. doi: 10.1155/2015/401956. Epub 2015 Nov 22.


Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Townsend S, Fennell BJ, Apgar JR, Lambert M, McDonnell B, Grant J, Wade J, Franklin E, Foy N, Ní Shúilleabháin D, Fields C, Darmanin-Sheehan A, King A, Paulsen JE, Hickling TP, Tchistiakova L, Cunningham O, Finlay WJ.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15354-9. doi: 10.1073/pnas.1510944112. Epub 2015 Nov 30.


Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products.

Yin L, Chen X, Vicini P, Rup B, Hickling TP.

Cell Immunol. 2015 Jun;295(2):118-26. doi: 10.1016/j.cellimm.2015.03.002. Epub 2015 Mar 14. Review.


A review of quantitative modeling of B cell responses to antigenic challenge.

Hickling TP, Chen X, Vicini P, Nayak S.

J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):445-59. doi: 10.1007/s10928-014-9388-7. Epub 2014 Oct 19. Review.


A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications.

Chen X, Hickling TP, Vicini P.

CPT Pharmacometrics Syst Pharmacol. 2014 Sep 3;3:e134. doi: 10.1038/psp.2014.31.


A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.

Chen X, Hickling TP, Vicini P.

CPT Pharmacometrics Syst Pharmacol. 2014 Sep 3;3:e133. doi: 10.1038/psp.2014.30.


Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, McClure CP, Irving WL, Ball JK, Harris M, Hickling TP, Tarr AW.

J Innate Immun. 2014;6(5):676-84. doi: 10.1159/000362209. Epub 2014 May 15.


The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.

Palsson S, Hickling TP, Bradshaw-Pierce EL, Zager M, Jooss K, O'Brien PJ, Spilker ME, Palsson BO, Vicini P.

BMC Syst Biol. 2013 Sep 28;7:95. doi: 10.1186/1752-0509-7-95.


CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.

Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, Edmonds J, Fitz LJ, Miao W, Whitters MJ, Medley QG, Guo YJ, Darmanin-Sheehan A, Autin B, Shúilleabháin DN, Cummins E, King A, Krebs MR, Grace C, Hickling TP, Boisvert A, Zhong X, McKenna M, Francis C, Olland S, Bloom L, Paulsen J, Somers W, Jensen A, Lin L, Finlay WJ, Cunningham O.

MAbs. 2013 Nov-Dec;5(6):882-95. doi: 10.4161/mabs.26201. Epub 2013 Aug 21.


Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.

Müller MR, Saunders K, Grace C, Jin M, Piche-Nicholas N, Steven J, O'Dwyer R, Wu L, Khetemenee L, Vugmeyster Y, Hickling TP, Tchistiakova L, Olland S, Gill D, Jensen A, Barelle CJ.

MAbs. 2012 Nov-Dec;4(6):673-85. doi: 10.4161/mabs.22242.


CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization.

Platt RJ, Khodai T, Townend TJ, Bright HH, Cockle P, Perez-Tosar L, Webster R, Champion B, Hickling TP, Mirza F.

Cells. 2013 Jan 4;2(1):19-42. doi: 10.3390/cells2010019.


Preclinical studies of PF-04849285, an interferon-α8 fusion protein for the treatment of HCV.

Flores MV, Hickling TP, Sreckovic S, Fidock MD, Horscroft N, Katragadda M, Savic B, Rawal J, Delpuech-Adams OE, Robas N, Corey T, Nelms L, Lawton M, Marcek J, Stubbs M, Westby M, Ciaramella G.

Antivir Ther. 2012;17(5):869-81. doi: 10.3851/IMP2099. Epub 2012 Apr 13. Erratum in: Antivir Ther.2012;17(5):939.


Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry.

Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, Ball JK, Sim RB, Tarr AW, Hickling TP.

Protein Cell. 2010 Jul;1(7):664-74. doi: 10.1007/s13238-010-0088-9. Epub 2010 Jul 29.


Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.

Hamed MR, Tarr AW, McClure CP, Ball JK, Hickling TP, Irving WL.

J Viral Hepat. 2008 May;15(5):339-45. doi: 10.1111/j.1365-2893.2007.00947.x. Epub 2008 Jan 22.


Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

Tarr AW, Owsianka AM, Jayaraj D, Brown RJ, Hickling TP, Irving WL, Patel AH, Ball JK.

J Gen Virol. 2007 Nov;88(Pt 11):2991-3001.


Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex.

Brown KS, Keogh MJ, Tagiuri N, Grainge MJ, Presanis JS, Ryder SD, Irving WL, Ball JK, Sim RB, Hickling TP.

Clin Exp Immunol. 2007 Jan;147(1):90-8.


Mannan binding lectin and viral hepatitis.

Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP.

Immunol Lett. 2007 Jan 15;108(1):34-44. Epub 2006 Nov 20. Review.


Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.

Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK.

J Virol. 2006 Sep;80(17):8695-704.


Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK.

Hepatology. 2006 Mar;43(3):592-601.


Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets.

Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, Vitelli A, Dubuisson J, Patel AH, Ball JK, Borrow P.

J Gen Virol. 2005 Sep;86(Pt 9):2507-12.


Collectins and their role in lung immunity.

Hickling TP, Clark H, Malhotra R, Sim RB.

J Leukoc Biol. 2004 Jan;75(1):27-33. Epub 2003 Sep 12. Review.


Humoral autoreactivity directed against surfactant protein-A (SP-A) in rheumatoid arthritis synovial fluids.

Trinder PK, Hickling TP, Sim RB, Brackertz D, Loos M, Maeurer MJ.

Clin Exp Immunol. 2000 Apr;120(1):183-7.


Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells.

Hickling TP, Malhotra R, Bright H, McDowell W, Blair ED, Sim RB.

Viral Immunol. 2000;13(1):125-35.


A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo.

Hickling TP, Bright H, Wing K, Gower D, Martin SL, Sim RB, Malhotra R.

Eur J Immunol. 1999 Nov;29(11):3478-84.


Supplemental Content

Loading ...
Support Center